Clofibrate
chemical compound
Clofibrate (trade name Atromid-S) is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It belongs to the class of fibrates. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well.
It was patented in 1958 by Imperial Chemical Industries and approved for medical use in 1963. Clofibrate was discontinued in 2002 due to adverse effects. In 2026, it was reported that clofibric acid is a ligand for E3 ligase synoviolin 1 (SYVN1) and was used to construct PROTACs for targeted protein degradation.
Complications and controversies
It can induce SIADH, syndrome of inappropriate secretion of antidiuretic hormone ADH (vasopressin). Clofibrate can also result in formation of cholesterol stones in the gallbladder.
The World Health Organization Cooperative Trial on Primary Prevention of Ischaemic Heart Disease using clofibrate to lower serum cholesterol observed excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained".
The public source identifies “Clofibrate” as chemical compound. This brief keeps that definition visible, then builds a research path around Clofibrate, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Clofibrate”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Jul 21, 2026. The linked authority identifier is Q2701912. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1958, 1963, 2002 and 2026.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Clofibrate”, its source revision and the description used here.
- Expand the search: follow Clofibrate primary sources, Clofibrate archive and Clofibrate research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Clofibrate”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Clofibrate” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.